Formulation strategies for sustained release of proteins

Papers of special note have been highlighted as: ▪ of interest

Bibliography

• 1  World Health Organisation. Adherence to Long-term Therapies – Evidence for Action. ISBN: 9241545992 (2003).
  Google Scholar
• 2  Folkman J, Long DM. The use of silicone rubber as a carrier for prolonged drug therapy. Surg. Res.4,139–142 (1964).
  Medline CASGoogle Scholar
• 3  Heller J. Patient-friendly bioerodible drug delivery systems. J. Control. Release133,88–89 (2009).
  Medline CASGoogle Scholar
• 4  Kosobucki BR, Freeman WR, Cheng L. Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrectomised eye. Br. J. Ophthalmol.90,705–708 (2006).
  Medline CASGoogle Scholar
• 5  Govardhan C, Khalaf N, Jung CW et al. Novel long acting crystal formulation of human growth hormone. Pharm. Res.22(9),1461–1470 (2005).
  Medline CASGoogle Scholar
• 6  Kim SJ, Hahn SK, Kim MJ et al. Development of a novel sustained release formulation of recombinant human growth hormone using sodium hyaluronate microparticles. J. Control. Release104,323–335 (2005).
  Medline CASGoogle Scholar
• 7  Hahn SK, Kim SJ, Kim MJ, Kim DH. Characterisation and in vivo study of sustained release formulation of human growth hormone using sodium hyaluronate. Pharm. Res.21(8),1374–1381 (2004).
  Medline CASGoogle Scholar
• 8  Bidlingmaier M, Kim J, Savoy C et al. Comparative pharmacokinetics and pharmacodynamics of a new sustained release growth hormone, LB03002, versus daily GH in adults with GH deficiency. J. Clin. Endo. Met.91(8),2926–2930 (2006).
  Medline CASGoogle Scholar
• 9  Peter F, Savoy C, Ji HJ et al. Pharmacokinetic and pharmacodynamic profile of a new sustained release GH formulation, LB03002, in children with GH deficiency. Eur. J. Endo.160,349–355 (2009).
  Medline CASGoogle Scholar
• 10  Chang TMS. Semipermeable microcapsules. Science146 (3643),524–525 (1964).
  Medline CASGoogle Scholar
• 11  Chang TMS, Poznansky MJ. Semipermeable microcapsules containing catalase for enzyme replacement in acatalasaemic mice. Nature218,243–245 (1968).
  Medline CASGoogle Scholar
• 12  Folkman J, Langer R. Polymers for the sustained release of proteins and other macromolecules. Nature263,797–800 (1976).
  MedlineGoogle Scholar
• 13  Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Delivery Rev.28,5–24 (1997).
  Medline CASGoogle Scholar
• 14  Blasi P, D’Souza SS, Selmin F, DeLuca PP. Plasticizing effect of water on poly(lactide-co-glycolide). J. Control. Release108,1–9 (2005).
  Medline CASGoogle Scholar
• 15  Tracey MA, Ward KL, Firouzabadian L et al. Factors affecting the degradation rate of PLGA microspheres in vivo and in vitro. Biomaterials20,1057–1062 (1999).
  MedlineGoogle Scholar
• 16  Passerini N, Craig DQM. An investigation into the effects of residual water on the glass transition temperature of polylactide microspheres using modulated DSC. J. Control. Release73,111–115 (2001).
  Medline CASGoogle Scholar
• 17  Wang J, Wang BM, Shwendeman SP. Characterisation of the initial burst release of a model peptide from poly(d,l-lactide-co-glycolide) microspheres. J. Control. Release82,289–307 (2002).
  Medline CASGoogle Scholar
• 18  Fu K, Pack DW, Klibanov AM, Langer R. Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm. Res.17(1),100–106 (2000).
  Medline CASGoogle Scholar
• 19  Ding AG, Schwendeman SP. Acidic microclimate pH distribution in PLGA microspheres monitored by confocal laser scanning microscopy. Pharm. Res.25(9),2041–2052 (2008).
  Medline CASGoogle Scholar
• 20  Li L, Schwendeman SP. Mapping microclimate pH in PLGA microspheres. J. Control. Release101,163–173 (2005).
  Medline CASGoogle Scholar
• 21  Ding AG, Shenderova A, Schwendeman SP. Prediction of microclimate pH in poly(lactic-co-glycolic acid) films. J. Am. Chem. Soc.128,5384–5390 (2006).
  Medline CASGoogle Scholar
• 22  Klose D, Siepmann F, Elkharraz K, Siepmann J. PLGA-based drug delivery systems – importance of the type of drug and device geometry. Int. J. Pharm.354(1–2),95–103 (2008).
  Medline CASGoogle Scholar
• 23  Miller RA, Brady JM, Cutright DE. Degradation rates of oral resorbable implants (polylactates and polyglycolates): rate modification with changes in PLA/PGA copolymer ratios. J. Biomed. Mater. Res.11,711–719 (1977).
  Medline CASGoogle Scholar
• 24  Dunne M, Corrigan OI, Ramtoola Z. Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glucolide particles. Biomaterials21,1659–1668 (2000).
  Medline CASGoogle Scholar
• 25  Perez-Marrero R, Tyler RC. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin. Pharmacother.5(2),447–457 (2004).
  Medline CASGoogle Scholar
• 26  Brodbeck KJ, Pushpala S, McHugh AJ. Sustained release of human growth hormone from PLGA solution depots. Pharm. Res.16(12),1825–1829 (1999).
  Medline CASGoogle Scholar
• 27  Shah NH, Railkar AS, Chen FC et al. A biodegradable injectable implant for delivering micro and macromolecules using PLGA copolymers. J. Control. Release27,391–147 (1993).
  Google Scholar
• 28  Graham PD, Brodbeck KJ, McHugh AJ. Phase inversion dynamics of PLGA solutions related to drug delivery. J. Control. Release58,233–245 (1999).
  Medline CASGoogle Scholar
• 29  Brodbeck KJ, DesNoyer JR, McHugh AJ. Phase inversion dynamics of PLGA solutions related to drug delivery – Part II the role f solution thermodynamics and batch-side mass transfer. J. Control. Release62,333–344 (1999).
  Medline CASGoogle Scholar
• 30  Dunn RL, Tipton AJ, Menardi EM. A biodegradable in-situ forming drug delivery system. Proc. Intern. Symp. Control. Release Bioact. Mater.18,456–466 (1991).
  Google Scholar
• 31  Schoenhammer K, Petersen H, Guethlein F, Goepferich A. Injectable in situ forming depot systems: PEG-DAE as a novel solvent for improved PLGA storage stability. Int. J. Pharm.371,33–39 (2009).
  Medline CASGoogle Scholar
• 32  Schoenhammer K, Petersen H, Guethlein F, Goepferich A. Poly(ethylene glycol)500 dimethylether as a novel solvent for injectable in situ forming depots. Pharm. Res.26(12),2568–2577 (2009).
  Medline CASGoogle Scholar
• 33  Shively ML, Coonts BA, Renner WD, Southard SL, Bennett AT. Physicochemical characterisation of a polymeric injectable implant delivery system. J. Control. Release33,237–243 (1995).
  CASGoogle Scholar
• 34  Astaneh R, Erfan M, Moghimi H, Mobedi H. Changes in morphology of in situ forming PLGA implant prepared by different polymer molecular weight and its effect on release behaviour. J. Pharm. Sci.98(1),135–145 (2009).
  Medline CASGoogle Scholar
• 35  Astaneh R, Nafissi-Varcheh N, Erfan M. Zinc–leuprolide complex: preparation, physicochemical characterisation and release behaviour from in situ forming implant. J. Peptide Sci.13,649–654 (2007).
  Medline CASGoogle Scholar
• 36  Ravivarapu HB, Moyer KL, Dunn RL. Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide. Int. J. Pharm.194,181–191 (2000).
  Medline CASGoogle Scholar
• 37  Jain RA, Rhodes CT, Railkar AM et al. Controlled release of drugs from a novel injectable in situ formed biodegradable PLGA microsphere system. Pharm. Sci.1(Suppl. 1),S298 (1998).
  Google Scholar
• 38  Luan X, Bodmeier R. Influence of the PLGA type on the leuprolide release from in situ forming microparticle systems. J. Control. Release110,266–272 (2006).
  Medline CASGoogle Scholar
• 39  Luan X, Bodmeier R. In situ forming microparticle system for drug delivery of leuprolide acetate: influence of the formulation and processing parameters. Eur. J. Pharm. Sci.27,143–149 (2006).
  Medline CASGoogle Scholar
• 40  Kranz H, Bodmeier R. A novel in situ forming drug delivery system for controlled parenteral drug delivery. Int. J. Pharm.332,107–114 (2007).
  Medline CASGoogle Scholar
• 41  Okumu F, Dao LN, Fielder PJ et al. Sustained delivery of human growth hormone from a novel gel system: SABER™. Biomaterials23,4353–4358 (2002).
  Medline CASGoogle Scholar
• 42  Pechenov S, Shenoy B, Yang MX, Basu SK, Margolin AL. Injectable controlled release formulations incorporating protein crystals. J. Control. Release96,149–158 (2004).
  Medline CASGoogle Scholar
• 43  Tae G, Kornfield JA, Hubbell JA. Sustained release of human growth hormone from in situ forming hydrogels using self-assembly of fluoroalkyl-ended poly(ethylene glycol). Biomaterials26,5259–5266 (2005).
  Medline CASGoogle Scholar
• 44  Ruiz-Hornillos J, Henriquez-Santana A, Moreno-Fernandez A et al. Systemic allergic dermatitis caused by the solvent of Eligard. Contact Dermatitis61(6),355–356 (2009).
  Medline CASGoogle Scholar
• 45  Jeong B, Bae YH, Lee DS, Kim SW. Biodegradable block co-polymers as injectable drug delivery systems. Nature388,860–862 (1997).
  Medline CASGoogle Scholar
• 46  Zentner GM, Rathi R, Shih C et al. Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J. Control. Release72,203–215 (2001).
  Medline CASGoogle Scholar
• 47  Chen S, Singh J. Controlled release of growth hormone from thermosensitive triblock copolymer systems: in vitro and in vivo evaluation. Int. J. Pharm.352,58–65 (2008).
  Medline CASGoogle Scholar
• 48  Katakam M, Ravis WR, Banga AK. Controlled release of human growth hormone in rats following parenteral administration of poloxamers gels. J. Control. Release49,21–26 (1997).
  CASGoogle Scholar
• 49  Katakam M, Ravis WR, Golden DL, Banga AK. Controlled release of human growth hormone following subcutaneous administration in dogs. Int. J. Pharm.152,53–58 (1997).
  CASGoogle Scholar
• 50  Chen PC, Park YJ, Chang LC et al. Injectable microparticle-gel system for prolonged and localised lidocaine release. I. In vitro characterization. J. Biomed. Mater. Res.70(3),412–419. (2004).
  Google Scholar
• 51  Chen PC, Kohane DS, Park YJ et al. Injectable microparticle-gel system for prolonged and localised lidocaine release. II. In vivo anesthetic effects. J. Biomed. Mater. Res.70A,459–466 (2004).
  CASGoogle Scholar
• 52  Ricci EJ, Bentley MVLB, Farah M, Bretas RES, Marchettis JM. Rheological characterisation of poloxamers 407 lidocaine hydrochloride gels. Eur. J. Pharm. Sci.17,161–167 (2002).
  Medline CASGoogle Scholar
• 53  Ricci EJ, Lunardi LO, Nanclares DMA, Marchetti JM. Sustained release of lidocaine from poloxamers gels. Int. J. Pharm.288,235–244 (2005).
  Medline CASGoogle Scholar
• 54  Zhang L, Parsons DL, Navarre C, Kompella UB. Development and in vitro evaluation of sustained release poloxamers 407 gel formulations of ceftiofur. J. Control. Release85,73–81 (2002).
  Medline CASGoogle Scholar
• 55  Johnston TP, Punjabi MA, Froelich CJ. Sustained delivery of interleukin-2 from a poloxamers 407 gel matrix following intraperitoneal injection in mice. Pharm. Res.9(3),425–434 (1992).
  Medline CASGoogle Scholar
• 56  Katakam M, Banga AK. Use of poloxamers polymers to stabilise recombinant human growth hormone against various processing stresses. Pharm. Dev. Tech.2(2),143–149 (1997).
  Medline CASGoogle Scholar
• 57  Jiang Z, You Y, Deng XM, Hao JY. Injectable hydrogels of poly(ε-caprolactone-co-glycolide)-co-poly(ethylene glycol)-poly(ε-caprolactone-co-glycolide) triblock copolymer aqueous solutions. Polymer48,4786–4792 (2007).
  Google Scholar
• 58  Van de Weert M, Hennink WE, Jiskoot W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm. Res.17(10),1159–1167 (2000).▪ Excellent review on protein instability in poly(lactide-co-glycolide) (PLGA) microparticles: on encapsulation, release and storage.
  Medline CASGoogle Scholar
• 59  Jiang Z, Hao J, You Y, Qun G, Cao W, Deng X. Biodegradable thermogelling hydrogel of P(CL-GL)-PEG-P(CL-GL) triblock copolymer: degradation and drug release behaviour. J. Pharm. Sci.98(8) 2603–2610 (2009).
  Medline CASGoogle Scholar
• 60  Jain RA. The manufacturing technologies of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials21,2475–2490 (2000).
  Medline CASGoogle Scholar
• 61  Freitas S, Merkle HP, Gander B. Microencapsulation by solvent extraction/evaporation: reviewing the state of the art of microsphere preparation process technology. J. Control. Release102,313–332 (2005).
  Medline CASGoogle Scholar
• 62  O’Donnell PB, McGinty JW. Preparation of microspheres by the solvent evaporation technique. Adv. Drug Delivery Rev.28,25–42 (1997).
  MedlineGoogle Scholar
• 63  Sukumar M, Storms SM, De Felippis MR. Non-native intermediate conformational states of human growth hormone in the presence of organic solvents. Pharm. Res.22(5),789–796 (2005).
  Medline CASGoogle Scholar
• 64  Sah H. Protein behaviour at the water/methylene chloride interface. J Pharm. Sci., 88(12),1320–1325 (1999).
  Medline CASGoogle Scholar
• 65  Cleland JL, Jones AJS. Stable formulations of recombinant human growth hormone and interferon- γ for microencapsulation in biodegradable microspheres. Pharm. Res.13(10),1464–1475 (1996).
  Medline CASGoogle Scholar
• 66  Castellanos IJ, Cruz G, Crespo R, Greibenow K. Encapsulation induced aggregation and loss in activity of γ-chymotrypsin and their prevention. J. Control. Release81,307–319 (2002).▪ Use of Fourier transform infrared to probe protein structure and demonstrate the ability of polyethylene glycol to stabilize proteins during encapsulation.
  Medline CASGoogle Scholar
• 67  Kim HK, Park TG. Microencapsulation of human growth hormone within biodegradable polyester microspheres: protein aggregation stability and incomplete release mechanism. Biotech. Bioeng.65(6) 659–667 (1999).
  Medline CASGoogle Scholar
• 68  Perez C, Griebenow K. Effects of salts on lysozyme stability at the water-oil interface and upon encapsulation in PLGA microspheres. Biotech. Bioeng.82(7) 825–832 (2003).
  Medline CASGoogle Scholar
• 69  Perez C, Griebenow K. Improved activity and stability of lysozyme at the water/CH₂Cl₂ interface: enzyme unfolding and aggregation and its prevention by polyols. J. Pharm. Pharmacol.53,1217–1226 (2001).
  Medline CASGoogle Scholar
• 70  Van de Weert M, Hoechstetter J, Hennink WE, Crommelin DJA. The effect of a water/organic solvent interface on the structural stability of lysozyme. J. Control. Release68,351–359 (2000).
  Medline CASGoogle Scholar
• 71  Carrasquillo KG, Carro JCA, Alejandro A, Toro DD, Greibenow K. Reduction of structural perturbations in bovine serum albumin by non-aqueous microencapsulation. J. Pharm. Pharmacol.53,115–120 (2001).
  Medline CASGoogle Scholar
• 72  Pérez C, De Jesus P, Griebenow K. Preservation of lysozyme structure and function upon encapsulation and release from poly(lactic-co-glycolic) acid microspheres prepared by the water-in-oil-in-water method. Int. J. Pharm.248,193–206 (2002).
  Medline CASGoogle Scholar
• 73  Cleland JL, Mac A, Boyd B et al. The stability of recombinant human growth hormone in poly(lactic-co-glycolic acid) PLGA microspheres. Pharm. Res.14(4) 420–425 (1997).
  Medline CASGoogle Scholar
• 74  Cleland JL, Duenas E, Daugherty A et al. Recombinant human growth hormone poly(lactic-co-glycolic acid) (PLGA) microspheres provide a long lasting effect. J. Control. Release49,193–205 (1997).
  CASGoogle Scholar
• 75  Cleland JL, Johnson O, Putney S, Jones AJS. Recombinant human growth hormone poly(lactic-co-glycolic acid) microsphere formulation development. Adv. Drug Delivery Rev.28,71–84 (1997).▪ Informative review of the development of the only injectable sustained-release protein formulation to reach the market: Nutropin Depot™.
  Medline CASGoogle Scholar
• 76  Kwak HH, Shim WS, Choi MK et al. Development of a sustained release recombinant human growth hormone formulation. J. Control. Release137,160–165 (2009).
  Medline CASGoogle Scholar
• 77  Castellanos IJ, Flores G, Griebenow K. Effect of cyclodextrins on α-chymotrypsin stability and loading in PLGA microspheres upon s/o/w emulsion. J. Pharm. Sci.95(4) 849–858 (2006).
  Medline CASGoogle Scholar
• 78  Quaglia F, De Rosa G, Granata E et al. Feeding liquid, non-ionic surfactant and cyclodextrin affect the properties of insulin-loaded poly(lactide-co-glycolide) microspheres prepared by spray drying. J. Control. Release86,267–278 (2003).
  Medline CASGoogle Scholar
• 79  De Rosa G, Larobina D, La Rotonda MI et al. How cyclodextrin incorporation affects the properties of protein-loaded PLGA-based microspheres: the case of insulin/hydroxypropyl-β-cyclodextrin. J. Control. Release102,71–83 (2005).
  Medline CASGoogle Scholar
• 80  Bezemer JM, Radersma R, Grijpma DW et al. Zero-order release of lysozyme from poly(ethylene glycol)/poly(butylenes terephthalate matrices. J. Control. Release64,179–192 (2000).
  Medline CASGoogle Scholar
• 81  Bezemer JM, Radersma R, Grijpma DW, Dijkstra PJ, van Blitterswijk CA, Feijen J. Microspheres for protein delivery prepared from amphiphilic multibock copolymers 1 influence of preparation techniques on particle characteristics and protein delivery. J. Control. Release67,233–248 (2000).
  Medline CASGoogle Scholar
• 82  Van Dijkhuizen-Radersma R, Nicolas HM, van de Weert M et al.Stability aspects of salmon calcitonin entrapped in poly(ether ester) sustained release systems, Int. J. Pharm.248,229–237 (2002).
  Medline CASGoogle Scholar
• 83  Griebenow K, Kilbanov AM. On protein denaturation in aqueous-organic mixtures but not in pure organic solvents. J. Am. Chem. Soc.118(47),11695–11700 (1996).
  CASGoogle Scholar
• 84  Carrasquillo KG, Stabley AM, Aponte-Carro JC et al. Non-aqueous encapsulation of excipient-stabilised spray-freeze dried BSA into poly(lactide-co-glycolide) microspheres results in release of native protein. J. Control. Release76,199–208 (2001).
  Medline CASGoogle Scholar
• 85  Petit DK, Lawter JR, Huang WJ et al.Characterisation of poly(glycolide-co-d,l-lactide)/poly(D,L-lactide) microspheres for controlled release of GM-CSF. Pharm. Res.14(10),1422–1430 (1997).
  MedlineGoogle Scholar
• 86  Constantino HR, Johnson OL, Zale SE. Relationship between encapsulated drug particle size and initial release of recombinant human growth hormone from biodegradable microspheres. J. Pharm Sci.93(10),2624–2634 (2004).
  MedlineGoogle Scholar
• 87  Takada S, Yamagata Y, Misaki M, Taira K, Kurokawa T. Sustained release of human growth hormone from microcapsules prepared by a solvent evaporation technique. J. Control. Release88,229–242 (2003).
  Medline CASGoogle Scholar
• 88  Castellanos IJ, Carrasquillo KG, Lopez JDJ, Alvarez M, Griebenow K. Encapsulation of bovine serum albumin in poly(lactide-co-glycolide) microspheres by the solid-in-oil-in-water technique. J. Pharm. Pharmacol.53,167–178 (2001).
  Medline CASGoogle Scholar
• 89  Wang J, Chua KM, Wang CH. Stabilisation and encapsulation of human immunoglobulin G into biodegradable microspheres. J. Col. Inter. Sci.271,92–101 (2004).
  Medline CASGoogle Scholar
• 90  Kim TK, Burgess DJ. Pharmacokinetic characterisation of ¹⁴C-vascular endothelial growth factor controlled release microspheres using a rat model. J. Pharm. Pharmacol.54,897–905 (2002).
  Medline CASGoogle Scholar
• 91  Zhu G, Mallery SR, Schwendeman SP. Stabilisation of proteins encapsulated in injectable poly(lactide-co-glycolide). Nature Biotech.18,52–57 (2000).▪ Demonstration of the ability of inorganic bases to counter the pH drop inside PLGA and poly(lactic acid) drug delivery systems as they degrade and prevent protein degradation.
  Medline CASGoogle Scholar
• 92  Kang J, Schwendeman SP. Comparison of the effects of Mg(OH)₂ and sucrose on the stability of bovine serum albumin encapsulated in injectable poly(D,L-lactide-co-glycolide) implants. Biomaterials23,239–245 (2002).
  Medline CASGoogle Scholar
• 93  Castellanos IJ, Crespo R, Griebenow K. Poly(ethylene glycol) as stabiliser and emulsifying agent: a novel stabilisation approach preventing aggregation and inactivation of proteins upon encapsulation in bioerodible polyester microspheres. J. Control. Release88,135–145 (2003).
  Medline CASGoogle Scholar
• 94  Castellanos IJ, Griebenow K. Improved α-chymotrypsin stability upon encapsulation in PLGA microspheres by solvent replacement. Pharm. Res.20(11),1873–1880 (2003).
  Medline CASGoogle Scholar
• 95  Morita T, Sakamura Y, Horikiri Y, Suzuki T, Yoshino H. Protein encapsulation into biodegradable microspheres by a novel s/o/w emulsion method using poly(ethylene glycol) as a protein micronisation adjuvant. J. Control. Release69,435–444 (2000).
  Medline CASGoogle Scholar
• 96  Morita T, Horikiri Y, Suzuki T, Yoshino H. Applicability of various amphiphilic polymers to the modification of protein release kinetics from biodegradable reservoir-type microspheres. Eu. J. Pharm. Biopharm.51,45–53 (2001).
  Medline CASGoogle Scholar
• 97  Takada S, Yamagata Y, Misaki M, Taira K, Kurokawa T. Sustained release of human growth hormone from microcapsules prepared by a solvent evaporation technique. J. Control. Release88,229–242 (2003).
  MedlineGoogle Scholar
• 98  Takada S, Kurokawa T, Misaki M, Taira K, Yamagata Y. A new animal model for the evaluation of long-term growth rate over one month by rhGH/PLGA microcapsule formulations. J. Pharm. Pharmacol.55,951–961 (2003).
  Medline CASGoogle Scholar
• 99  Takenaga M, Yamaguchi Y, Kitagawa A, Ogawa Y, Mizushima Y, Igarashi R. A novel sustained release formulation of insulin with dramatic reduction in rapid release. J. Control. Release79,81–91 (2002).
  Medline CASGoogle Scholar
• 100  Yamaguchi Y, Takenaga M, Kitagawa A, Ogawa Y, Mizushima Y, Igarashi R. Insulin-loaded biodegradable PLGA microcapsules: initial burst release controlled by hydrophilic additives. J. Control. Release81,235–249 (2002).
  Medline CASGoogle Scholar
• 101  Takenaga M, Yamaguchi Y, Kitagawa A et al. Optimum formulation for sustained release insulin. Int. J. Pharm.271,85–94 (2004).
  Medline CASGoogle Scholar
• 102  Takenaga M, Yamaguchi Y, Kitagawa A, Ogawa Y, Mizushima Y, Igarashi R. A novel insulin formulation can keep providing steady levels of insulin for much longer periods in vivo. J. Pharm. Pharmacol.54,1189–1194 (2002).
  Medline CASGoogle Scholar
• 103  Tracy MA. Development and scale-up of a microsphere protein delivery system. Biotechnol. Prog.14,108–115 (1998).▪ Unique insight into the industrial scale-up and development of an injectable sustained-release formulation made using a novel encapsulation technology.
  Medline CASGoogle Scholar
• 104  Johnson OL, Cleland JL, Lee HJ et al. A month-long effect from a single injection of microencapsulated human growth hormone. Nature Med.2,795–799 (1996).
  Medline CASGoogle Scholar
• 105  Johnson OL, Jaworowicz W, Cleland JL et al. The stabilisation and encapsulation of human growth hormone into biodegradable microspheres. Pharm. Res.14(6),730–735 (1997).
  Medline CASGoogle Scholar
• 106  Lee HJ, Riley G, Johnson O et al.In vivo characterisation of sustained release formulations of human growth hormone. J. Pharmacol. Exp. Thera.281(3),1431–1439 (1997).
  Medline CASGoogle Scholar
• 107  Reiter EO, Attie KM, Moshang T et al. A multicenter study of the efficacy and safety of sustained release GH in the treatment of naive pediatric patients with GH deficiency. J. Clin. Endo. Met.86(10),4700–4706 (2001).
  Medline CASGoogle Scholar
• 108  Kemp SF, Fielder PJ, Attie KM et al. Pharmacokinetic and pharmacodynamic characteristics of a long acting growth hormone (GH) preparation (Nutropin^® Depot) in GH-deficient children. J. Clin. Endo. Met.89(7),3234–3240 (2004).
  Medline CASGoogle Scholar
• 109  Howdle SM, Watson MS, Whitaker MJ et al. Supercritical fluid mixing: preparation of thermally sensitive polymer composites containing bioactive materials. Chem. Commun.2001,109–110 (2001).
  Google Scholar
• 110  Watson MS, Whitaker MJ, Howdle SM, Shakesheff KM. Incorporation of proteins into polymer materials by a novel supercritical fluid processing method. Adv. Mater.14(24),1802–1804 (2002).
  CASGoogle Scholar
• 111  Hao J, Whitaker MJ, Wong B, Serhatkulu G, Shakesheff KM, Howdle SM. Plasticization and spraying of poly(D,L-lactic acid) using supercritical carbon dioxide: control of particle size. J. Pharm. Sci.93(4),1083–1090 (2004).
  Medline CASGoogle Scholar
• 112  Hao J, Whitaker MJ, Wong B, Serhatkulu G, Shakesheff KM, Howdle SM. Supercritical fluid assisted melting of poly(ethylene glycol): a new solvent-free route to microparticles. J. Mater. Chem.15,1148–1153 (2005).
  CASGoogle Scholar
• 113  Whitaker MJ, Hao J, Davies OR et al. The production of protein-loaded microparticles by supercritical fluid enhanced mixing and spraying. J. Control. Release101,85–92 (2005).
  Medline CASGoogle Scholar
• 114  Jordan F, Naylor A, Kelly CA, Howdle SM, Lewis A, Illum L. Sustained release hGH microsphere formulation produced by a novel supercritical fluid technology: in vivo studies. J. Control. Release141,153–160 (2010).
  Medline CASGoogle Scholar
• 115  Reslow M, Jonsson M, Laakso T. Sustained release of human growth hormone from PLG-coated starch microspheres. Drug Del. Sys. Sci.2,103–109 (2002).
  Google Scholar
• 116  Jostel A, Mukherjee A, Alenfall J, Smethurst L, Shalet AM. A new sustained release preparation of human growth hormone and its pharmacokinetic, pharmacodynamic and safety profile. Clin. Endo.62,623–627 (2005).
  Medline CASGoogle Scholar
• 117  Stenekes RJH, Franssen O, van Brommel EMG, Crommelin DJA, Hennink WE. The preparation of dextran microspheres in an all-aqueous system: effect of formulation parameters on particle characteristics. Pharm. Res.15(4),557–561 (1998).
  Medline CASGoogle Scholar
• 118  Franssen O, Vandervennet L, Roders P, Hennink WE. Degradable dextran hydrogels: controlled release of a model protein from cylinders and microspheres. J. Control. Release60,211–221 (1999).
  Medline CASGoogle Scholar
• 119  Vlugt-Wensink KDF, Meijer YJ, van Steenbergen MJ et al.Effect of excipients on the encapsulation efficiency and release of human growth hormone from dextran microspheres. Eur. J. Pharm. Biopharm.67,589–596 (2007).
  Medline CASGoogle Scholar
• 120  Vlugt-Wensink KDF, de Vreuh R, Gresnigt MG et al. Preclinical and clinical in vitro in vivo correlation of an hGH dextran microsphere formulation. Pharm. Res.24(12),2239–2248 (2007).
  Medline CASGoogle Scholar
• 121  Moore WV, Leppert P. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J. Clin. Endo. Met.51(4),691–697 (1980).
  Medline CASGoogle Scholar
• 122  Woo BH, Jiang G, Jo YW, DeLuca PP. Preparation and characterisation of a composite PLGA and poly(acryloyl hydroxyethyl starch) microsphere system for protein delivery. Pharm. Res.18(11),1600–1606 (2001).
  Medline CASGoogle Scholar
• 123  Capan Y, Jiang G, Giovagnoli S, Na KH, DeLuca PP. Preparation and characterisation of poly(D,L-lactide-co-glycolide) microspheres for controlled release of human growth hormone. AAPS PharmSciTech4(2) 1–10 (2003).
  Google Scholar
• 124  Jiang G, Qiu W, DeLuca PP. Preparation and in vitro-in vivo evaluation of insulin loaded poly(acryloyl hydroxyethyl starch)-PLGA composite microspheres. Pharm. Res.20(3),452–459 (2003).
  Medline CASGoogle Scholar
• 125  Schoubben A, Blasi P, Giovagnoli S, Perioli L, Rossi C, Ricci M. Novel composite microparticles for protein stabilisation and delivery. Eur. J. Pharm. Sci.36,226–234 (2009).
  Medline CASGoogle Scholar
• 126  Johansen P, Tamber H, Merkle P, Gander B. Diphtheria and tetanus toxoid microencapsulation into conventional and end-group alhylated PLA/PLGAs. Eu. J. Pharm. Biopharm.47,193–201 (1999).
  Medline CASGoogle Scholar
• 127  Agrawal CM, Athanasiou KA. Technique to control pH in vicinity of biodegrading PLA-PLGA implants. J. Biomed. Mater. Res.38,105–114 (1997).
  Medline CASGoogle Scholar
• 128  Shao PG, Bailey LC. Stabilisation of pH-induced degradation of porcine insulin in biodegradable polyester microspheres. Pharm. Dev. Technol.4,633–642 (1999).
  Medline CASGoogle Scholar
• 129  Kim HK, Park TG. Comparative study on sustained release of human growth hormone from semi-crystalline poly(L-lactic acid) and amorphous poly(D,L-lactic-co-glycolic acid) microspheres: morphological effect on protein release. J. Control. Release98,115–125 (2004).
  Medline CASGoogle Scholar
• 130  Kim HK, Chung HJ, Park TG. Biodegradable polymeric microspheres with open/closed pores for sustained release of human growth hormone. J. Control. Release112,167–174 (2006).
  Medline CASGoogle Scholar
• 131  Bae SE, Son JS, Park K, Han DK. Fabrication of covered porous PLGA microspheres using hydrogen peroxide for controlled drug delivery and regenerative medicine. J. Control. Release133,37–43 (2009).
  Medline CASGoogle Scholar
• 132  Lucke A, Kiermaier J, Gopferich A. Peptide acylation by poly(α-hydroxy esters). Pharm. Res.19(2),175–181 (2002).
  Medline CASGoogle Scholar
• 133  Murty SB, Goodman J, Thanoo BC, DeLuca PP. Identification of chemically modified peptide from poly(lactide-co-glycolide) microspheres under in vitro release conditions. AAPS PharmSciTech4(4),E50 (2003).
  MedlineGoogle Scholar
• 134  Murty SB, Thanoo BC, Wei Q, DeLuca PP Impurity formation studies with peptide loaded polymeric microspheres Part I. In vivo evaluation. Int. J. Pharm.297,50–61 (2005).
  Medline CASGoogle Scholar
• 135  Murty SB, Dong HN, Thanoo BC, DeLuca PP. Impurity formation studies with peptide loaded polymeric microspheres Part II. In vitro evaluation. Int. J. Pharm.297,62–72 (2005).
  Medline CASGoogle Scholar
• 136  Ibrahim MA, Ismail A, Fetouch MI, Gopferich A. Stability of insulin during the erosion of poly(lactic acid) and poly(lactic-co-glycolic acid) microspheres. J. Control. Release106,241–252 (2005).
  Medline CASGoogle Scholar
• 137  Lam XM, Duenas ET, Cleland JL. Encapsulation and stabilisation of nerve growth factor into poly(lactic-co-glycolic) acid microspheres. J. Pharm. Sci.90(9),1356–1365 (2001).
  Medline CASGoogle Scholar
• 138  Tsai T, Mehta RC, DeLuca PP. Adsorption of peptides to poly(D,L-lactide-co-glycolide):1 effect of physical factors. Int. J. Pharm.127,31–42 (1996).
  CASGoogle Scholar
• 139  Tsai T, Mehta RC, DeLuca PP. Adsorption of peptides to poly(D,L-lactide-co-glycolide):2 effect of solution properties on the adsorption. Int. J. Pharm.127,43–52 (1996).
  CASGoogle Scholar
• 140  Calis S, Jeyanthi R, Tsai T, Mehta RC, DeLuca PP. Adsorption of salmon calcitonin to PLGA microspheres. Pharm. Res.12(7),1072–1076 (1995).
  Medline CASGoogle Scholar
• 141  Mehta RC, Jeyanthi R, Calis S, Thanoo BC, Burton KW, DeLuca PP. Biodegradable microspheres as depot system for parenteral delivery of peptide drugs. J. Control. Release29,375–384 (1994).
  CASGoogle Scholar
• 142  Jiang G, Woo BH, Kang F, Singh J, DeLuca PP. Assessment of protein release kinetics, stability and protein polymer interaction of lysozyme encapsulated poly(D,L-lactide-co-glycolide) microspheres. J. Control. Release79,137–145 (2002).
  Medline CASGoogle Scholar
• 143  Jiang W, Schwendeman SP. Stabilisation and controlled release of bovine serum albumin encapsulated in poly(D,L lactide) and poly(ethylene glycol) microsphere blends. Pharm. Res.18(6),878–885 (2001).
  Medline CASGoogle Scholar
• 144  Diaz RV, Soriano I, Delgado A, Llabres M, Evora C. Effect of surfactant agents on the release of ¹²⁵I-bovine calcitonin from PLGA microspheres: in vitro–in vivo study. J. Control. Release43,59–64 (1997).
  CASGoogle Scholar
• 145  De Rosa G, Iommelli R, La Rotonda MI, Miro A, Quaglia F. Influence of the co-encapsulation of different non-ionic surfactants on the properties of PLGA insulin-loaded microspheres. J. Control. Release69,283–295 (2000).
  MedlineGoogle Scholar
• 146  Chan YP, Meyrueix R, Kravtzoff R, Nicolas F, Lundstrom K. Review on Medusa^®: a polymer-based sustained release technology for protein and peptide drugs. Expert Opin. Drug Del.4(4),441–451 (2007).
  Medline CASGoogle Scholar
• 201  Eligard prescribing information http://products.sanofi-aventis.us/eligard/eligard_75.html
  Google Scholar
• 202  OctoPlus press release, June 2009 http://observer.OctoPlus.nl/index.cfm/OctoPlus/news-centre/news-releases/index.cfm?news-article=OctoPlus-licensee-biolex-completes-patient-enrollment-in-phase-iib-study-with-locteron
  Google Scholar
• 203  Genentech press release, 1 June 2004 www.gene.com/gene/news/press-releases/display.do?method=detail&id=7447
  Google Scholar
• 204  Flamel Technologies press release, 18 December 2009 www.flamel.com/pressReleases/2009.shtml
  Google Scholar